Anna Brook is a highly skilled attorney versed in all aspects of intellectual property litigation, with particular focus on pharmaceutical and Hatch-Waxman patent litigation, consumer product and fiber optic component patent litigation, and trademark disputes. She has extensive experience advising senior management in connection with IP transactions, strategy, and monetization of IP portfolios.
She represents clients during all stages of intellectual property disputes, from pre-trial investigation to trial and appeal.
Some of her prior representative experience includes representing Orexo in multiple Hatch-Waxman litigations involving the company’s entire product portfolio; representing AstraZeneca in Hatch-Waxman cases against multiple defendants relating to Nexium and Prilosec products; representing Tris Pharma in litigation relating to extended release liquid and chewable products to treat ADHD; and representing The Sun Products Corporation in patent lawsuit involving single dose laundry detergent.
Ms. Brook provides counsel to executive management in connection with (i) the acquisition, protection, and enforcement of IP rights and (ii) the management and monetization of IP portfolios. She is also experienced with due diligence investigations of IP in corporate transactions and providing strategic advice concerning research and development agreements, license agreements, and collaboration agreements.
Ms. Brook previously served as the editor-in-chief of the Harvard Law Record.